Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416351 | 1.00 | ADRB2 (0.65) | ADRB2ADRB1LMNAKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL9142587 | 0.98 | ADRB2 (0.63) | ADRB2ADRB1LMNAKMT2AMEN1 | |
| SCHEMBL4050984 | 0.89 | LMNA (0.59) | ADRB2ADRB1LMNAKMT2AMEN1 | |
| SCHEMBL1241813 | 0.88 | LMNA (0.73) | ADRB2ADRB1LMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL10922740 | 0.87 | ADRB2 (0.71) | ADRB2ADRB1KMT2AMEN1L3MBTL1 | |
| SCHEMBL3723068 | 0.85 | ADRB2 (0.59) | ADRB2ADRB1KMT2AMEN1L3MBTL1 | |
| SCHEMBL10457357 | 0.84 | ADRB2 (0.63) | ADRB2ADRB1KMT2AMEN1L3MBTL1 | |
| SCHEMBL15958920 | 0.84 | ADRB2 (0.59) | ADRB2ADRB1KMT2AMEN1L3MBTL1 | |
| SCHEMBL28079221 | 0.84 | ADRB2 (0.59) | ADRB2ADRB1KMT2AMEN1L3MBTL1 | |
| SCHEMBL1496789 | 0.82 | TSHR (0.71) | ADRB2ADRB1KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101374791-B | Method for producing optically active alcohol compound | SUMITOMO CO LTD | 2012-07-18 | — | — | CN | disclosed |
| CN-101374792-B | Method for producing optically active alcohol compound | SUMITOMO CHEMICAL CO | 2012-03-28 | — | — | CN | disclosed |
| US-7906667-B2 | Method for producing optically active alcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-15 | — | — | US | disclosed |
| CN-101103967-B | Medicine composition containing bevantolol hydrochloride | HAINAN SHENGKE LIFE SCIENT RES INST | 2011-01-19 | — | — | CN | disclosed |
| US-20100234629-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-7728179-B2 | Method for producing optically active alcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-01 | — | — | US | disclosed |
| EP-1380342-B1 | COMPLEX CATALYST, PROCESS FOR PRODUCING THE COMPLEX CATALYST, AND PROCESS FOR PRODUCING ALCOHOL DERIVATIVE WITH THE COMPLEX CATALYST | SUMITOMO CHEMICAL CO (JP) | 2009-07-01 | — | — | EP | disclosed |
| CN-101374791-A | Method for producing optically active alcohol compound | SUMITOMO CHEMICAL CO (JP) | 2009-02-25 | — | — | CN | disclosed |
| CN-101374792-A | Method for producing optically active alcohol compound | SUMITOMO CHEMICAL CO (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-20090012330-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1982972-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1982973-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
| CN-101103967-A | Medicine composition containing bevantolol hydrochloride | HAINAN SHENGKE LIFE SCIENT RES (CN) | 2008-01-16 | — | — | CN | disclosed |
| CN-1281320-C | Complex catalyst process for producing the complex catalyst and process for producing alcohol derivative with the complex catalyst | SUMITOMO CHEMICAL CO (JP) | 2006-10-25 | — | — | CN | disclosed |
| CN-1503696-A | Complex catalyst, process for producing the complex catalyst, and process for producing alcohol derivative using the complex catalyst | ס�ѻ�ѧ��ҵ��ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| EP-1380342-A1 | COMPLEX CATALYST, PROCESS FOR PRODUCING THE COMPLEX CATALYST, AND PROCESS FOR PRODUCING ALCOHOL DERIVATIVE WITH THE COMPLEX CATALYST | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-0492615-B1 | Process for producing biguanide derivative | IDEMITSU KOSAN CO (JP) | 1995-03-08 | — | — | EP | disclosed |
| US-5286905-A | Heating hydrogen halide salt of phenoxyalkylamine with dicyandiamide in paraffinic hydrocarbon solvent | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1994-02-15 | — | — | US | disclosed |
| EP-0492615-A1 | Process for producing biguanide derivative | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1992-07-01 | — | — | EP | disclosed |
| US-4016186-A | JUVENILE HORMONE ACTIVITIES, PESTICIDES | KYOWA HAKKO KOGYO CO., LTD. (JA) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012330-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | ADH1A, ADH1C, ADH5 | ADRB2 1220/4885ADRB1 528/4885LMNA 3411/4885 |
| US-20100234629-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | ADH1A, ADH1C, ADH5 | ADRB2 1584/4885ADRB1 609/4885LMNA 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.